View this email in your browser Spotlight: Payton Nyquvest Chairman & CEO, Numinus Wellness Inc Numinus recently completed an oversubscribed private placement with gross proceeds of over C$6,000,000, and is expected to go public in April on the TSXV under the symbol $NUMI. You can read our previous company feature on Numinus here What do you think is the most important thing for people to understand about the future of psychedelics? I think the most important thing to understand both presently and in the future in regards to psychedelics is what the science and research is showing us. These tools, in conjunction with a trained practitioner in a safe set and setting have huge potential to alleviate many of the mental illnesses that plague society today. What inspired you to build a business in the psychedelic space? These treatments saved my life when I thought I was out of options, and I have seen time and time again the impact they have had on other people's lives as well. Health care needs more tools in their toolbox and psychedelics has the potential to really help with not only patient outcomes but also alleviate the huge weight on the current health care systems shoulders. What is the most common misconception you hear about psychedelics? There needs to be more education around what is being researched and approved in the use of psychedelics. As it's been said many times before, but this is not the "next cannabis" in terms of model or approach. What would you say to potential investors considering plant medicines as a space to invest? Do your homework, and support models that are based off creating something that is sustainable and can create lasting change. These medicines have the potential to greatly impact the way we look at treatment in healthcare. The groups that will be successful are those that are focused on patient and client outcomes. What trend do you think is emerging in the world of psychedelics and what impact do you see that having? There is a wonderful merging of tech and science with psychedelics that could greatly enhance not only the outcome of the treatment, but also continuing to aid research as well as client/patient safety. What obstacles do you think psychedelics will need to overcome from an investment perspective?



There is still some stigma around psychedelics and a need for more education on how they are being researched and used. Right now we believe the best way to address that is by supporting the science and research from credible sources.